Advances in hematopoietic stem cell mobilization procedures have enabled Bioverativ Inc. to bring its enhancer-targeted therapy, BIVV003, into the clinic for sickle cell disease. FDA accepted the IND for BIVV003 on Wednesday, and the company expects to start Phase I/II testing this year.
Under a 2014 deal with the Sanofi (Euronext:SAN; NYSE:SNY) unit’s then parent, Biogen Inc. (NASDAQ:BIIB), Sangamo Therapeutics Inc. (NASDAQ:SGMO) is developing the same therapy as ST-400 for β-thalassemia. FDA accepted an IND for ST-400 last fall, and Sangamo plans to start a Phase I/II trial this half.
BIVV003 (ST-400) comprises autologous hematopoietic stem...